Current and future anti-TNF therapy for inflammatory bowel disease

Papadakis KA, Targan SR: Tumor necrosis factor: biology and therapeutic implications. Gastroenterology 2000, 119:1148–1157.

Papadakis KA, Targan SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000, 51:289–298.

Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997, 337:1029–1035.

Rutgeerts P, D’Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999, 117:761–769.

Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541–1549.

Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004, 126:402–413.

Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999, 5:119–133.

Remicade (infliximab) for intravenous injection [package insert]. Horsham, PA: Centocor, Inc.; 2003.

Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098–1104.

Morelli J, Wilson FA: Does administration of infliximab increase susceptibility to listeriosis? Am J Gastroenterol 2000, 95:841–842.

Kamath BM, Mamula P, Baldassano RN, Markowitz JE: Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 2002, 34:410–412.

Warris A, Bjorneklett A, Gaustad P: Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001, 344:1099–1100.

Nakelchik M, Mangino JE: Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002, 112:78.

Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999, 340:1398–1405.

Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004, 350:876–885.

Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601–608.

Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003, 124:917–924.

Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323–333.

Sandborn WJ, Hanauer SB, Lukas M, et al.: Maintenance of remission over 1 year in patients with active Crohn’s disease treated with adalimumab: results of a blinded, placebo-controlled trial [abstract]. Am J Gastroenterol 2005, 100:S311.

Sandborn WJ, Hanauer SB, Lukas M, et al.: Remission and clinical response induced and maintained in patients with active Crohn’s disease treated for 1-year open-label with adalimumab [abstract]. Am J Gastroenterol 2005, 100:S316.

Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007, 132:52–65.

Sandborn WJ, Rutgeerts P, Hanauer SB, et al.: Adalimumab rapidly induces clinical remission and response in patients with moderate to severe Crohn’s disease who had secondary failure to infliximab therapy: results of the GAIN study [abstract]. Paper presented at ACG Annual Scientific Meeting, 2006. Las Vegas; October 20–26, 2006.

Furst DE, Schiff MH, Fleischmann RM, et al.: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis). J Rheumatol 2003, 30:2563–2571.

Weinblatt ME, Keystone EC, Furst DE, et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35–45.

Van de Putte LB, Atkins C, Malaise M, et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63:508–516.

Keystone EC, Kavanaugh AF, Sharp JT, et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a fully human anti tumor necrosis factor-alpha monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400–1411.

Sandborn WJ, Feagan BG, Stoinov S, et al.: Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn’s disease: results from a 26-week, placebo-controlled phase III study (PRECiSE 1) [abstract]. Gastroenterology 2006, 130(Suppl 2):A107–A108.

Schreiber S, Lawrence IC, McColm JA, et al.: Certolizumab pegol, a humanised anti-TNF PEGylated Fab’ fragment, is safe and effective in the maintenance of response and remission following induction in Crohn’s disease: a phase III study (PRECiSE 2) [abstract]. Gut 2005, 54(Suppl VII):A82.

Schreiber S, Feagan B, Hanauer S, et al.: Safety and tolerability of subcutaneous (SC) certolizumab pegol in active Crohn’s disease (CD): results from two phase III studies (PRECiSE program) [abstract]. Gastroenterology 2006, 130(Suppl 2):A479.

Sandborn WJ, Feagan BG, Radford-Smith G, et al.: CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn’s disease: a randomized, double blind, placebo controlled trial. Gut 2004, 53:1485–1493.

Feagan BG, Sandborn WJ, Lichtenstein GR, et al.: CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006, 23:617–628.

Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088–1094.

Rutgeerts P, Sandborn WJ, Fedorak RN, et al.: Onercept for moderate-to-severe Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006, 4:888–893.

Ehrenpreis ED, Kane SV, Cohen LB, et al.: Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 1999, 117:1271–1277.

Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al.: An open-label pilot study of low dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology 1999, 117:1278–1287.

Bauditz J, Wedel S, Lochs H: Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease. Gut 2002, 50:196–200.

Sabate JM, Villarejo J, Lemann M, et al.: An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn’s disease. Aliment Pharmacol Ther 2002, 16:1117–1124.

Facchini S, Candusso M, Martelossi S, et al.: Efficacy and long-term treatment with thalidomide in children and young adults with Crohn’s disease: preliminary results. J Pediatr Gastroenterol Nutr 2001, 32:178–181.

Hommes D, Van der Blink B, Plasse T, et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease. Gastroenterology 2002, 122:7–14.

Regueiro M, Mardini H: Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003, 9:98–103.

Topstad DR, Panaccione R, Heine JA, et al.: Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rates in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum 2003, 46:577–583.

Van der Hagen SJ, Baeten CG, Soeters PB, et al.: Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn’s disease: a preliminary report. Dis Colon Rectum 2005, 48:758–767.

Talbot C, Sagar PM, Johnston MJ, et al.: Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Colorectal Dis 2005, 7:164–168.

Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy in ulcerative colitis. N Engl J Med 2005, 353:2462–2476.

Evans RC, Clarke L, Heath P, et al.: Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997, 11:1031–1035.